Neoplasms
Conditions
Keywords
Metastatic Cancer
Brief summary
The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.
Interventions
PROCEDUREBiopsy
Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Response assessment of complete response (CR), partial response (PR), or long-term stable disease (SD) for \>6 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial. * Availability of tissue sample.
Exclusion criteria
* Pregnant, lactating, or intending to become pregnant during the study. * Participants receiving CPI treatment as part of a non-Roche/Genentech clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Gene Alterations in at-Progression Biopsy of Patricipants with Acquired Immune Escape | Day 1 | Number of Gene Alterations Will Be Evaluated Using NGS Approaches by Comparing At-Progression Biopsy with Pre-Treatment Biopsy |
Countries
France, South Korea, Spain, United Kingdom, United States
Outcome results
None listed